Home › Research › Treatments
Sertraline for the treatment of depression in Alzheimer disease: genetic influences
Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J et al.. Journal of geriatric psychiatry and neurology, 2011-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To assess the potential for genetic influences on sertraline treatment efficacy for depression of Alzheimer disease (dAD). Four functional genetic variants were studied: 2 serotonin receptors (HTR2A-T102C and HTR2C-Cys23Ser), the serotonin transporter (5HTT-LPR), and brain-derived neurotrophic factor (BDNF-Val66Met). Treatment response by genotype was measured by (1) the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression. Methods We utilized data from the Depression in Alzheimer's Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD. Proportional odds logistic regression and mixed effects models were used to examine the above mentioned outcome measures. Results No significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks. Discussion Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed. Future studies should continue to examine the interaction of depression-related genetic variants with antidepressant treatment in Alzheimer disease patients with depression.
What this study adds
Evidence grade: High
This analysis of data from a trial that found no significant effect of sertraline on depression in Alzheimer's disease found no significant link between any of the four genetic variants studied and treatment outcomes. It does not show a way to treat, cure or prevent Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Peters, M. E., Vaidya, V., Drye, L. T., Rosenberg, P. B., Martin, B. K., Porsteinsson, A. P., et al. (2011). Sertraline for the treatment of depression in Alzheimer disease: genetic influences. Journal of geriatric psychiatry and neurology. https://doi.org/10.1177/0891988711422527
Vancouver
Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, et al. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. Journal of geriatric psychiatry and neurology. 2011. doi:10.1177/0891988711422527. PMID: 22228829.
BibTeX
@article{peters2011-22228829,
author = {Peters, M. E. and Vaidya, V. and Drye, L. T. and Rosenberg, P. B. and Martin, B. K. and Porsteinsson, A. P. and Frangakis, C. E. and Mintzer, J. and others},
title = {{Sertraline for the treatment of depression in Alzheimer disease: genetic influences}},
journal = {Journal of geriatric psychiatry and neurology},
year = {2011},
doi = {10.1177/0891988711422527},
pmid = {22228829},
url = {https://doi.org/10.1177/0891988711422527}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods We utilized data from the Depression in Alzheimer's Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD.
- Results No significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks.
- Discussion Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed.
Why it matters
This analysis of data from a trial that found no significant effect of sertraline on depression in Alzheimer's disease found no significant link between any of the four genetic variants studied and treatment outcomes. It does not show a way to treat, cure or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of geriatric psychiatry and neurology) |
| Journal's citation record | 1 / 4 | Journal of Geriatric Psychiatry and Neurology: journal h-index 105 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 14 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.8 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Dimitrios Avramopoulos: h-index 62 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22228829) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.